The new Chairman of NICE discusses value-based pricing, cost-benefit appraisals of drugs for rare diseases and the organization's expanded remit.  For more details go to http://www.nature.com/nrd/journal/v12/n7/full/nrd4053.html?WT.ec_id=NRD-201307